Pomerantz investigates Astrana Health after 9.02% stock drop following research report
AI Summary- Pomerantz LLP is investigating Astrana Health and certain officers or directors on behalf of investors.
- Astrana shares fell $3.40, or 9.02%, to $34.30 on September 17, 2026.
- Glass House Research published a report raising concerns about acquisitions, estimates, a $545 million loan and 2027 Medicare exposure.